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Abstract
Background: Intrahepatic cholestasis of pregnancy (ICP) is the most common liver disorder specific to pregnancy
and presents with maternal pruritus, raised concentrations of serum bile acids and abnormal liver function tests. ICP
is associated with increased rates of spontaneous and iatrogenic preterm labour, fetal hypoxia, meconium-stained
amniotic fluid and intrauterine death. Some clinicians treat ICP with ursodeoxycholic acid (UDCA) to improve
maternal pruritus and biochemical abnormalities. However, there are currently no data to support the use of UDCA
to improve pregnancy outcome as none of the trials performed to date have been powered to address this
question.
Methods: The PITCHES trial is a triple-masked, placebo-controlled randomised trial, to evaluate UDCA versus
placebo in women with ICP between 20 + 0 to 40 + 6 weeks’ gestation. The primary objective of the trial is to
determine if UDCA treatment of women with ICP between 20 + 0 and 40 + 6 weeks’ gestation reduces the primary
perinatal outcome: a composite of perinatal death (as defined by in utero fetal death after randomisation or known
neonatal death up to 7 days) or preterm delivery (less than 37 weeks’ gestation) or neonatal unit admission for at
least 4 h (from infant delivery until hospital discharge). The secondary objectives of the trial are (1) to investigate
the effect of UDCA on other short-term outcomes for both mother and infant and (2) to assess the impact of
UDCA on health care resource use, in terms of the total number of nights for mother and infant, together with
level of care.
Discussion: Current practice in the UK at the time of trial commencement for the treatment of ICP is inconsistent,
with some units routinely prescribing UDCA, others prescribing very little and the remainder offering it variably. Our
previous pilot trial of UDCA in women with ICP demonstrated that the trial would be feasible, and the research
question remains active and unanswered. Results are highly likely to influence clinical practice, through direct
management and impact on national and international guidelines.
Trial registration: ISRCTN registry, ID: ISRCTN91918806. Prospectively registered on 27 August 2015.
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Background
Intrahepatic cholestasis of pregnancy (ICP), also called
obstetric cholestasis, is the most common liver disorder
specific to pregnancy. It presents with maternal pruritus,
raised concentrations of serum bile acids and abnormal
liver function tests. The maternal symptoms typically re-
solve postpartum, but affected women have an increased
risk of hepatobiliary disease in later life [1]. ICP is asso-
ciated with increased rates of spontaneous and iatro-
genic preterm labour, fetal hypoxia and meconium-
stained amniotic fluid [2–4]. There are also reports of
increased rates of intrauterine death [5–7], although the
incidence is low [4, 8]. Some clinicians treat ICP with
ursodeoxycholic acid (UDCA) [9, 10] to improve mater-
nal pruritus and biochemical abnormalities. However,
there are currently no data to support the use of UDCA
to improve pregnancy outcome as none of the trials per-
formed to date have been powered to address this
question.
UDCA is a naturally occurring bile acid that is present
in small amounts in humans. It is relatively hydrophilic
and has several actions that result in improvement of
cholestasis. It increases biliary bile-acid excretion by
post-translational modification of hepatic bile-acid trans-
porters, enhances renal bile-acid excretion and has
anti-apoptotic effects [11]. UDCA improves outcomes in
primary biliary cirrhosis in addition to maternal symp-
toms in ICP [12]. Adverse events are only infrequently
reported in pregnancy [13]; some women experience
gastrointestinal side-effects (such as diarrhoea), but in
the largest trial to date there were no significant differ-
ences in the incidence of reported side-effects in UDCA
and placebo groups [2]. Other therapeutic options in
ICP include rifampicin, cholestyramine, S-adenosyl me-
thionine, guar gum and dexamethasone, but the small
studies of these drugs in women with ICP have not con-
sistently shown that they improve maternal symptoms
or serum bile-acid concentrations [3].
The main clinical research question is whether adverse
pregnancy outcomes can be reduced in women with ICP
by treatment with UDCA. This is a subject of intense
debate. The current UK guideline (from the Royal Col-
lege of Obstetricians and Gynaecologists) on the man-
agement of ICP describes the evidence relating to the
use of UDCA and states that ‘UDCA improves pruritus
and liver function in women with obstetric cholestasis’
but ‘women should be informed of the lack of robust
data concerning protection against stillbirth and safety
to the fetus or neonate’. The guideline concludes that:
‘as the pathophysiology of obstetric cholestasis and the
mechanism of fetal demise are uncertain, the possible
role of UDCA is unclear. Further larger studies are re-
quired to determine this’. The latest updated Cochrane
review [13] judged many of the trials of UDCA in ICP to
be at moderate to high risk of bias. Trials to date have
lacked power to demonstrate whether UDCA is fetopro-
tective, with numbers of participants and adverse events
too small to enable the recommendation of UDCA. The
Cochrane review concluded that larger trials of UDCA
to determine fetal benefits or risks are needed.
If UDCA is found to be beneficial in ameliorating ad-
verse perinatal outcomes, once published these results
would be highly likely to lead to an immediate change in
clinical practice, through individual choice of clinicians
and women, and through changing national/inter-
national guidelines.
The PITCHES trial is a triple-masked, placebo-con-
trolled randomised trial to evaluate UDCA versus pla-
cebo in women with ICP between 20+ 0 to 40+ 6 weeks’
gestation. The primary objective of the trial is to deter-
mine if UDCA treatment of women with ICP between
20+ 0 and 40+ 6 weeks’ gestation reduces adverse perinatal
outcomes up to infant hospital discharge. The secondary
objectives of the trial are (1) to investigate the effect of
UDCA on other short-term outcomes for both mother
and infant and (2) to assess the impact of UDCA on
health care resource use, in terms of the total number of
nights for mother and infant, together with level of care.
Methods
Study setting
The study will be conducted in approximately 30
consultant-led maternity units in England and Wales. A
list of participating study sites is available on the study
website: www.npeu.ox.ac.uk/pitches.
Inclusion criteria
Women will be considered eligible for inclusion into the
trial if they fit the following criteria:
 ICP (pruritus with a raised serum bile acid above
the upper limit of normal for the local laboratory)
 20+ 0 to 40+ 6 weeks’ gestation on day of
randomisation (see note below on gestational age)
 No known lethal fetal anomaly
 Singleton or twin pregnancy
 Aged 18 years or over
 Able to give written informed consent
Exclusion criteria
Women will be excluded from the trial if:
 A decision has already made for delivery within the
next 48 h
 There is a known allergy to any component of the
UDCA or placebo tablets
 there is a triplet or higher-order multiple pregnancy
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Intervention
The Investigational Medicine Product (IMP) is ursodeoxy-
cholic acid (UDCA) or matching placebo, manufactured
and supplied by Dr. Falk Pharma, GmBH. The most re-
cent Summary of Product Characteristics for UDCA can
be found at http://www.medicines.org.uk/emc/medicine/
27444. Possible side-effects include gastrointestinal disor-
ders (reported as common, i.e. ≥ 1/100 to < 1/10 patients)
or skin and subcutaneous disorders (reported as very rare,
i.e. < 1/10,000 patients), as listed in the Summary of Prod-
uct Characteristics.
Formulation and packaging
In the treatment arm, each film-coated tablet contains the
active ingredient: 500 mg UDCA and the inactive ingredi-
ents of magnesium stearate, polysorbate 80, providone K
25, microcrystalline cellulose, colloidal anhydrous silica,
crospovidone and talc. In the control arm, a matching pla-
cebo tablet, identical in colour and shape to the treatment
arm contains the inactive ingredients: magnesium stearate,
polysorbate 80, providone K 25, microcrystalline cellulose,
colloidal anhydrous silica, crospovidone and talc. The
coating ingredients for both are talc, hypromellose and
macrogol 6000. The IMP will be packaged into high-dens-
ity polyethylene bottles, with 32 tablets per bottle, and will
be administered orally. The IMP does not require any spe-
cial storage conditions.
Dosing
The starting dose will be 1000 mg daily (500 mg twice a
day), increased in increments of 500 mg per day every
3–14 days if there is no biochemical or clinical improve-
ment, based on clinical decision, to a maximum of
2000 mg per day. The dose of IMP may be reduced to
500 mg daily. Divided doses will be spread evenly
throughout the day. There is no need to take it with or
without food and this will be left to participant prefer-
ence. The IMP will be continued until delivery. The dur-
ation of treatment will range from 1 day to a maximum
of 22 weeks, for a participant randomised at 20 weeks’
gestation who does not deliver until 42 weeks. At each
antenatal follow-up visit with a member of the research
team, women will be asked the percentage of IMP that
they have taken since their last appointment and this
will be recorded.
Study procedures
Recruitment, eligibility and consent
Members of the research team will provide a full verbal
explanation and written description of the trial to
women who meet the inclusion criteria (as above). The
woman will be given sufficient time to consider the in-
formation, and to decide whether she will participate in
the trial. Written informed consent will be sought from
the woman and taken by an appropriately trained phys-
ician. Baseline data, including all demography, serum
bile-acid concentrations and liver function tests, together
with an itch visual analogue score (worst itch in the previ-
ous 24 h) completed by the woman will be entered on a
web-based database by members of the research team at
the time of study enrolment. On completion of these de-
tails, the database will issue a pack number to the local
hospital pharmacy for dispensing.
Participants will be reviewed at routine care clinic
visits until delivery. Serum bile acids and liver func-
tion tests will be monitored according to usual clin-
ical practice. The woman will be asked for a value of
the worst itch she felt during the previous 24 h. The
Investigational Medicinal Product (IMP) dose will be
altered at the discretion of the responsible clinician. If
maximal doses of the IMP have been reached, consid-
eration can be given to the addition of other therapy,
e.g. rifampicin, in addition to the trial therapy, with-
out breaking the allocation code. The remainder of
antenatal care, in particular the timing and mode of
delivery will be left to the discretion of the respon-
sible clinician. A schedule of participant enrolment,
interventions and assessments in the trial is shown in
Fig. 1.
A woman will be free to withdraw from the clinical
trial at any time without the need to provide any reason
or explanation; and that this decision will not impact on
any aspect of her ongoing clinical care. Women who
withdraw will be asked if they are willing for their out-
comes to be collected by case note review. If there is suf-
ficient time within the existing study time-line,
additional participants will be recruited up to the num-
ber of women who discontinued the intervention or
withdrew.
Outcomes will be recorded on the web-based database
through case note review by trained researchers after
discharge of the mother and baby.
The end of the trial will be defined as the date when
the trial database is locked. An end-of-trial declaration
will be made to the Medicines and Healthcare products
Regulatory Agency and the approving Research Ethics
Committee.
Outcomes
The primary perinatal outcome is a composite of peri-
natal death (as defined by in utero fetal death after ran-
domisation or known neonatal death up to 7 days) or
preterm delivery (less than 37 weeks’ gestation) or neo-
natal unit admission for at least 4 h (from infant delivery
until hospital discharge). Each infant will only be counted
once within this composite.
The secondary maternal outcomes are:
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 Maternal serum concentration (between randomisation
and delivery) of the following biochemical indices
of disease: bile acids; alanine transaminase;
aspartate transaminase; total bilirubin; gamma
glutamyl transferase
 Itch between randomisation and delivery, measured
by the worst episode of itch over the past 24 h
(millimetres on a visual analogue scale, assessed
at clinic visits)
 Gestational diabetes mellitus
Fig. 1 Schedule of participant enrolment, interventions and assessments in the trial. 1. All screening assessments are part of routine
clinical practice. 2. Weekly visits are recommended but not mandatory; normal hospital clinical practice is acceptable. 3. No other trial-
specific procedures are required before consent. 4. These blood tests are taken as per routine clinical practice and are not trial specific. 5.
Investigational Medicinal Product (IMP) started after randomisation. IMP dose altered by the research team if indicated by symptoms and/
or blood tests taken during normal clinical practice. 6. Cardiotocography only measured 1 week after randomisation or as per routine
clinical practice. 7. All unexpected adverse events occurring during the trial that are observed by the research team or reported by the
participant will be recorded in the electronic Case Report Form, whether or not attributed to the IMP. Unexpected serious adverse events
will be expeditiously reported. 8. All prescribed medications deemed necessary by the investigator to provide adequate supportive care
for ICP are permitted during the clinical trial. The medications must be recorded in the participant’s electronic Case Report Form; all
other concomitant medication will only be recorded in the event that a serious adverse event is reported
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 Mode of onset of labour
 Estimated blood loss after delivery
The secondary short-term perinatal outcomes are:
 In utero fetal death after randomisation
 Preterm delivery (less than 37 weeks’ gestation)
 Known neonatal death up to 7 days
 Neonatal unit admission for at least 4 h until infant
hospital discharge
 Mode of delivery classified as spontaneous vaginal,
instrumental vaginal or caesarean
 Total number of nights in the neonatal unit
 Birth weight
 Birth- weight centile
 Gestational age at delivery
 Presence of meconium
 APGAR score at 5 min
 Umbilical arterial pH at birth
The following secondary outcomes will be described
only and no formal statistical analysis comparing groups
will be conducted:
Maternal
 Maximum dose of trial medication required
 Need for additional therapy for cholestasis
 Assessment of myometrial contractions by
cardiotocography approximately 1 week (3–14 days)
post randomisation




 Known neonatal death up to 28 days
 Number of nights in each category of care
(intensive, high-dependency, special, transitional and
normal)
 Need for supplementary oxygen prior to discharge
 Number of days when supplemental oxygen is
required
 Need for ventilation support
 Abnormal cerebral ultrasound scan
 Confirmed sepsis (positive blood or cerebrospinal
fluid cultures)
 Necrotising enterocolitis (Bell’s stages 2 and 3)
 Seizures (confirmed by electroencephalography or
requiring anticonvulsant therapy)
 Encephalopathy (treated with hypothermia)
 Other indications and main diagnoses resulting in
neonatal unit admission for at least 4 h
The following health resource use post enrolment will
be captured for economic analysis:
 Maternal: total number of nights (antenatal,
intrapartum and postnatal) together with level of
care including adult Intensive Care Unit; mode of
delivery
 Infant: total number of nights for the infant in the
neonatal unit, together with level of care (e.g.
neonatal Intensive Care Unit)
 The cost of UDCA in the intervention group
All primary and secondary outcomes will be consid-
ered up to infant discharge home (from the hospital
where delivered) or transfer to another hospital.
Sample size
We will recruit 580 women in total; this will allow for
the possibility of 5% of infants being lost to follow-up
and is a conservative estimate given that some women
will have twin pregnancies. The sample size is informed
by the most recent Cochrane meta-analysis [13]. This in-
cludes the trials reported in the previous meta-analysis
[14] with the addition of the largest trial published in
2012 by our group [2]. From these data, we estimate the
event rate for the primary outcome (a composite of peri-
natal death or preterm delivery (less than 37 weeks’ ges-
tation) or neonatal unit admission) for infants of
untreated women as 40% with a plausible and relevant
reduction to 27% for infants of women treated with
UDCA, corresponding to an absolute risk reduction of
13% and a risk ratio (RR) of 0.675. This is conservative
compared with the effect sizes seen in the Cochrane
meta-analysis [13] for the three individual endpoints (RR
0.31, 0.46 and 0.48 for perinatal death, preterm delivery
and neonatal unit admission, respectively). Five hundred
and fifty infants of women with ICP (275 per group) are
required to have a 90% chance of detecting, as signifi-
cant at the two-sided 5% level, a reduction in the pri-
mary outcome measure from 40% in the control group
to 27% in the treated group. Allowing for 5% lost to
follow-up requires a total sample size of 580 infants (290
per group).
This number will also allow us to look at the compo-
nents of the composite endpoints: a trial assessing 550
infants will have 89% power to demonstrate a reduction
in neonatal unit admission rates from 17 to 8%, and 99%
power for a reduction in prematurity from 41 to 23%
(based on the Cochrane meta-analysis [13]), both effect
sizes of the same magnitude as that demonstrated in our
previous trial [2]. We do not anticipate enough perinatal
deaths to detect reliably any plausible treatment effect,
but we have included this due to its clinical importance
and will report it separately.
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The trial will be undertaken in approximately 30
consultant-led maternity units in England and Wales to
achieve this sample size in the anticipated time-frame.
Our previous pilot trial [2] has confirmed that women
and clinicians are willing to participate in this rando-
mised controlled trial and we have used recruitment es-
timates from this trial, together with trial management
experience and expertise of the Co-investigator Group
to inform strategies to meet the required target size.
Randomisation
The allocation ratio of intervention (UDCA) to control
(placebo) arms will be 1:1. Randomisation will be man-
aged via a secure web-based randomisation facility. A
minimisation algorithm will be used to ensure balance be-
tween the groups with respect to study centre (approxi-
mately 30 centres), gestational age at randomisation (< 34,
34 to < 37, ≥ 37 weeks’ gestation), single versus multi-fetal
pregnancy, and highest serum bile-acid concentration
prior to randomisation (< 40 μmol/L, ≥ 40 μmol/L).
The minimisation algorithm will be generated by
MedSciNet, which will hold the allocation code. Re-
search teams at sites will approach women to confirm
eligibility and the intervention will be allocated using the
web-based randomisation to provide an alpha numeric
pack number which will correlate with a pack to be dis-
pensed by that site’s pharmacy. The trial is triple-
masked: trial participants, clinical care providers, out-
come assessors and data analysts will all be masked to
allocation.
Emergency code break will be available, but clinicians
requesting unmasking must be satisfied that it is a genu-
ine emergency and that knowledge of the treatment allo-
cation (either UDCA or placebo) is needed to guide the
appropriate clinical management of the participant. In
some cases this may be achieved without unblinding, by
stopping the allocated treatment and treating the partici-
pant with UDCA.
Analysis
The analysis and presentation of results will follow the
most up-to-date recommendations of the Consolidated
Standards of Reporting Trials (CONSORT) group. Full
details of the Statistical Analysis Plan are given in
Additional file 1: Text S1. Analyses will be completed in
Stata® version 13.1 or later. Unmasked data will only be
made available for analysis after full database lock (after
all data outcomes have been completed) or on request
by the Data Monitoring Committee. All analyses will fol-
low the intention-to-treat principle, i.e. all randomised
women (and infants) will be analysed according to the
treatment that they were allocated to, irrespective of the
treatment they received or whether they received any
treatment at all.
Demographic and clinical data will be summarised
with counts and percentages for categorical variables,
means with standard deviations for normally distributed
continuous variables, and medians with interquartile or
simple ranges for other continuous variables. All com-
parative analyses will be performed adjusting for mini-
misation factors at randomisation [15]. Centre will be
included as a random effect. Both unadjusted and ad-
justed effect estimates will be presented, but the primary
inference will be based on the adjusted estimates.
Binary outcomes will be analysed using log binomial re-
gression models. Results will be presented as adjusted risk
ratios plus confidence intervals. If any model does not
converge, a Poisson regression model with robust variance
estimation will be used [16]. Continuous outcomes will be
analysed using linear regression models and results will be
presented as adjusted differences in means with confidence
intervals. Continuous outcomes will not be categorised for
statistical testing unless pre-specified as an outcome (and
clinically relevant). Unadjusted median differences with
confidence intervals will be presented for skewed continu-
ous variables, and an adjusted analysis using quantile re-
gression will be presented if possible. Analysis of outcomes
that are measured repeatedly over time (severity of itch
and biochemistry measures) will use repeated measures
analysis techniques. Alternatively, if the data are highly
skewed, geometric means of the post-randomisation obser-
vations will be reported [17] and the trial arms will be
compared using a geometric mean ratio, adjusted for the
baseline measures and minimisation factors.
The analysis of perinatal outcomes will include all in-
fants born to a randomised mother, so the denominator
will be the number of infants. For these outcomes, cor-
relations between twins will be accounted for in the ad-
justed model by nesting twin cluster as a random effect
within centre. Multiplicity (multi-fetal pregnancy) will
also be adjusted for as a fixed effect in the models.
Pre-specified subgroup analysis
Pre-specified subgroup analyses will be performed for
the primary outcome and its components, the bile-acid
and itch outcomes, using the statistical test of inter-
action (or test for trend). Binary outcomes will be pre-
sented as risk ratios with confidence intervals on a forest
plot. Pre-specified subgroups will be based on the cri-
teria selected for minimisation: serum bile-acid concen-
tration at baseline (10–39 μmol/L/ ≥ 40 μmol/L);
gestational age (participants recruited before 34 weeks,
34 to 36 + 6 weeks, ≥ 37 weeks’ gestation); singletons and
twins.
Sensitivity analyses
Sensitivity analyses will be conducted for the primary
outcome, itch and bile-acid concentration between
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randomisation and delivery, excluding mothers or in-
fants of mothers did not adhere to the intervention
(< 90% medication adherence consistently self-reported).
Level of statistical significance
Ninety-five percent confidence intervals will be used for
all primary and secondary outcome comparisons includ-
ing subgroup analysis.
Missing data
Missing data as a result of women or infants being lost
to follow-up are expected to be less than 5%. All
complete data items collected will be used. Case note re-
view will be conducted as usual on women who discon-
tinue the intervention, and on women who withdraw if
they indicated consent for outcome ascertainment.
Economic analysis
Data on mother and infant inpatient care and mode of
delivery will be costed using nationally published
sources. The cost of UDCA (derived from British Na-
tional Formulary, National Institute for Health and Care
Excellence) will also be included for women randomised
to receive the intervention. Descriptive statistics will be
reported including mean cost per participant and 95%
confidence intervals constructed using bootstrapping.
Assessment of safety and reporting
At each clinic visit, a member of the clinical or research
team will ask the woman if she has had any adverse
events, and will ensure that she has appropriate clinical
monitoring as routinely performed in each maternity
unit. Standard definitions of an adverse event, adverse
reaction, serious adverse event, serious adverse reaction
and suspected unexpected serious adverse reaction will
be followed. The relationship of each adverse event to
the IMP will be determined by a medically qualified in-
dividual according to the usual definitions of causality.
The period for safety reporting will be from first dose of
IMP until discharge of mother and discharge of infant.
Expectedness will be determined according to the Sum-
mary of Product Characteristics for UDCA. Standard
reporting guidelines will be followed.
The following expected adverse events and serious ad-
verse events are considered to be expected in this popu-
lation of pregnant women or a result of the routine
care/treatment of a participant and as such do not need
to be recorded:
 Worsening pruritus
 Admission in active labour
 Admission for cervical ripening or induction of
labour
 Admission for caesarean section
 Admission for assessment for suspected fetal
compromise, including poor growth, or reduced
fetal movements
 Admission for monitoring for hypertension,
antepartum haemorrhage, suspected preterm labour,
pre-labour rupture of the membranes or other reasons
for monitoring
 Admission for psychiatric or social reasons
 Admission for unstable lie or external cephalic
version.
The following fetal and neonatal outcomes are pre-
specified outcomes and as such will be recorded on
electronic Case Record Forms but not expeditiously
reported:
 Neonatal unit admission
 Stillbirth and perinatal death (within 7 days)
 Preterm delivery (< 37 completed weeks’ gestation)
 Meconium staining of the amniotic fluid or placenta
 Small for gestational age
 Seizures
 Encephalopathy (treated with hypothermia)
 Need for respiratory support – ventilation via an
endotracheal tube (ETT) or nasal continuous
positive airway pressure (CPAP)
 Sepsis requiring antibiotics with symptoms or
confirmed blood or cerebrospinal fluid (CSF) culture
An unexpected serious adverse event is any event that
meets the definition of a serious adverse event and is
not detailed in the list above as expected, including:
 Maternal death
 Maternal acute hepatic failure resulting in admission
to an intensive care setting or requiring liver
transplant
 Any unexpected fetal or perinatal death unrelated to
ICP
Quality control and assurance
Initiation of each participating centre will be performed
by the chief investigator or their delegate once all appro-
priate approvals are in place and the IMP has been
shipped to the site. During the trial, ongoing on-site and
central monitoring will be conducted.
The site principal investigator (PI), research midwife
and their delegates from each recruiting centre will be
fully trained in protocol adherence and able to deal with
site-specific issues. They will then be responsible for de-
livering this training to all relevant site staff prior to
opening their centre for recruitment. The PI and re-
search midwife will also promote the trial, and ensure
that all appropriate site staff, are kept fully appraised of
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issues such as recruitment status, informed consent, data
collection, follow-up and changing regulations, so that
the necessary recruitment targets are reached within the
timescale.
The trial coordinator will monitor recruitment against
targets, and monitor data collection completeness and
quality on a day-to-day basis.
Throughout the trial, there will be central monitoring,
overseen by the Project Management Group, Data Moni-
toring Committee, Trial Steering Committee and Quality
Assurance Team, ensuring good communication between
National Perinatal Epidemiology Unit trial team and the
site staff. Trial monitoring will be conducted in accord-
ance with the monitoring plan developed from the trial-
specific risk assessment. The monitor will visit sites where
anomalies are identified through central monitoring. Sites
that are identified as requiring additional support will be
visited by a member of the trial team or the monitor as
appropriate to the particular issues.
The Data Monitoring Committee will look regularly at
protocol adherence by site and by trial arm, including
randomisation processes and patterns of allocation.
Participant confidentiality, data handling and record
keeping
Data will be entered by trained researchers at site onto a
web-based database with pre-specified sense checks and
boundary checks. Data will be downloaded and stored
securely at the Clinical Trials Unit on a monthly basis as
a minimum. Data will be reviewed by midwife coordina-
tors and queries raised where clarification is needed.
Source data will be verified by a data monitor in 5% of
records by comparison of source data against electronic
data entry. Data management procedures will be carried
out in accordance with National Perinatal Epidemiology
Unit Clinical Trials Unit’s Standard Operating Proce-
dures and the principles outlined within MedSciNet
Clinical Trial Framework User Manual.
All paper documents will be stored securely and kept
in strict confidence in compliance with the Data Protec-
tion Act (1998) and all trial data will be stored in line
with the Medicines for Human Use (Clinical Trials)
Amended Regulations 2006. Due to the nature of preg-
nancy research, data will be kept for a period of no fewer
than 25 years in order to follow up on health-related is-
sues which may become relevant in the future. At all
times the personal data will be held securely and will
not be used for any other purpose.
The dataset will be available to appropriate academic
parties on request from the chief investigator in accord-
ance with the data-sharing policies of King’s College
London and the National Perinatal Epidemiology Unit
Clinical Trials Unit, with input from the Co-investigator
Group where applicable.
Discussion
Current practice in the UK at the time of trial com-
mencement for treatment of ICP is inconsistent, with
some units routinely prescribing UDCA, others prescrib-
ing very little and the remainder offering it variably. We
have engaged with all the sites to assess readiness and
willingness to participate for the duration of the trial
and offer women this placebo-controlled trial. We have
also worked for many years with the patient support
group, ICP Support, to ensure that we are providing ac-
curate, up-to-date information on treatment options for
women with ICP. Our previous pilot trial of UDCA in
women with ICP demonstrated that the trial would be
feasible and the research question remains active and
unanswered. Results are highly likely to influence clinical
practice, through direct management and impact on na-
tional and international guidelines.
Trial status
Protocol: Version 3.1: 5 April 2018. Final approval: 31 July
2015. Trial opened to recruitment: 23 October 2015. First
participant recruited: 23 December 2015. All 33 sites (30
NHS trusts) opened: 7 December 2016. End of recruit-
ment: 31 August 2018.
Additional files
Additional file 1: Text S1. Statistical Analysis Plan. (PDF 701 kb)
Additional file 2: Appendix 1. Participant information leaflet. (PDF 1717 kb)
Additional file 3: Appendix 2. Consent form. (PDF 366 kb)
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